Literature DB >> 1935507

Thyroid dysfunction and liver injury following alpha-interferon treatment of chronic viral hepatitis.

B Berris1, S V Feinman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1935507     DOI： 10.1007/bf01296413

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  13 in total

1.  An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer.

Authors:  I S Fentiman; F R Balkwill; B S Thomas; M J Russell; I Todd; G F Bottazzo
Journal:  Eur J Cancer Clin Oncol       Date:  1988-08

2.  Regulation of gene expression by interferons: control of H-2 promoter responses.

Authors:  B Korber; N Mermod; L Hood; I Stroynowski
Journal:  Science       Date:  1988-03-11       Impact factor: 47.728

3.  Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis.

Authors:  W J Mayet; G Hess; G Gerken; S Rossol; R Voth; M Manns; K H Meyer zum Büschenfelde
Journal:  Hepatology       Date:  1989-07       Impact factor: 17.425

Review 4.  Intrathyroidal MHC class II antigen expression and thyroid autoimmunity.

Authors:  T F Davies; L A Piccinini
Journal:  Endocrinol Metab Clin North Am       Date:  1987-06       Impact factor: 4.741

5.  Intrathyroidal HLA-DR expression and T lymphocyte phenotypes in Graves' thyrotoxicosis, Hashimoto's thyroiditis and nodular colloid goitre.

Authors:  R Jansson; A Karlsson; U Forsum
Journal:  Clin Exp Immunol       Date:  1984-11       Impact factor: 4.330

6.  Aberrant expression of HLA-DR antigen on thyrocytes in Graves' disease: relevance for autoimmunity.

Authors:  T Hanafusa; R Pujol-Borrell; L Chiovato; R C Russell; D Doniach; G F Bottazzo
Journal:  Lancet       Date:  1983-11-12       Impact factor: 79.321

7.  Induction of cytotoxic T-cell responses in vivo in the absence of CD4 helper cells.

Authors:  R M Buller; K L Holmes; A Hügin; T N Frederickson; H C Morse
Journal:  Nature       Date:  1987 Jul 2-8       Impact factor: 49.962

8.  Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.

Authors:  M B Atkins; J W Mier; D R Parkinson; J A Gould; E M Berkman; M M Kaplan
Journal:  N Engl J Med       Date:  1988-06-16       Impact factor: 91.245

9.  Susceptibility to thyroid autoimmune disease: molecular analysis of HLA-D region genes identifies new markers for goitrous Hashimoto's thyroiditis.

Authors:  K Badenhoop; G Schwarz; P G Walfish; V Drummond; K H Usadel; G F Bottazzo
Journal:  J Clin Endocrinol Metab       Date:  1990-11       Impact factor: 5.958

10.  Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon.

Authors:  P Burman; T H Tötterman; K Oberg; F A Karlsson
Journal:  J Clin Endocrinol Metab       Date:  1986-11       Impact factor: 5.958
View more
  10 in total

Review 1.  Hepatitis C virus infection in the elderly. Epidemiology, prophylaxis and optimal treatment.

Authors:  J Hayashi; S Kashiwagi
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

Review 2.  Nonhepatic manifestations and combined diseases in HCV infection.

Authors:  S J Hadziyannis
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

Review 3.  A practical guide to the use of interferons in the management of hepatitis virus infections.

Authors:  G Saracco; M Rizzetto
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

4.  Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy.

Authors:  N Custro; G Montalto; V Scafidi; M Soresi; S Gallo; S Tripi; A Notarbartolo
Journal:  J Endocrinol Invest       Date:  1997 Jul-Aug       Impact factor: 4.256

5.  Development of Sjögren's syndrome during treatment with recombinant human interferon-alpha-2b for chronic hepatitis C.

Authors:  H Unoki; A Moriyama; A Tabaru; A Masumoto; M Otsuki
Journal:  J Gastroenterol       Date:  1996-10       Impact factor: 7.527

Review 6.  [Interferon therapy and autoimmunity].

Authors:  J Fritzsch; J Krug; H J Heberling
Journal:  Med Klin (Munich)       Date:  1997-05-15

Review 7.  Clinical toxicity of the interferons.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1994-02       Impact factor: 5.606

8.  Development of transient thyroid disease and reaction during treatment of chronic hepatitis C with interferon.

Authors:  T Kodama; S Katabami; K Kamijo; A Katanuma; K Yamashita; N Azuma; T Tamaki; A Yachi
Journal:  J Gastroenterol       Date:  1994-06       Impact factor: 7.527

9.  A systematic review and meta-analysis of endocrine-related adverse events associated with interferon.

Authors:  Linghuan Wang; Binqi Li; He Zhao; Peixin Wu; Qingzhen Wu; Kang Chen; Yiming Mu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-05       Impact factor: 6.055

Review 10.  Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis.

Authors:  Chandrasekharan Nair Kesavachandran; Frank Haamann; Albert Nienhaus
Journal:  PLoS One       Date:  2013-02-01       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.